Baudax Bio Announces Full Commercial Launch of ANJESO™ and Receipt of Unique C-Code and Pass-Through Payment Status Effective July ...
MALVERN, Pa., June 15, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced the commercial launch of ANJESO™ (meloxicam) injection. ANJESO was approved by the U.S …